Loading condition report…
Loading condition report…
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
Neuropathic pain · Fibromyalgia-associated pain · Cancer-related pain · Chronic low-back pain
registered studies · not a treatment claimNeuropathic pain · Cancer-related pain · Fibromyalgia-associated pain · Chronic low-back pain
registered studies · not a treatment claimNeuropathic pain · Fibromyalgia-associated pain
Neuropathic pain · Fibromyalgia-associated pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimNeuropathic pain
document association · not a treatment claimHow treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. A study may appear under more than one route.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 12 of 18 unique registrations. 20 pattern memberships are preserved as badges; counts may overlap.
This 9-week study aimed to determine the efficacy, safety, and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with advanced cancer. Eligible participants were not required to stop any of their current treatments or medications.
Open study recordThis 9-week study aimed to determine the efficacy, safety and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with advanced cancer. Eligible participants were not required to stop any of their current treatments or medications.
Open study recordResearch frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
Showing 12 of 55 directly scoped registrations.
147 enrolled
Open study record468 enrolled
Open study record399 enrolled
Open study record48 enrolled
Open study record406 enrolled
Open study record397 enrolled
Open study record50 enrolled
Open study record558 enrolled
Open study record50 enrolled
Open study record161 enrolled
Open study record55 enrolled
Open study record25 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 14/09/2026 · 6,905 records · source sync still in progress
PROJECT NARRATIVE Policymakers are increasingly considering state medical cannabis laws as a potential solution to the U.S. opioid crisis, but rigorous evidence is lacking. In this project, we study the effects of state medical cannabis laws on receipt of prescription opioid and guideline-concordant non-opioid treatment, as well as treatment for opioid use disorder, opioid overdose, cannabis use disorder, and cannabis poisoning, among patients with chronic non-cancer pain.
Over the next 35 years, the “50+” population will more than double, and as greater than 50% of adults over 65 report bothersome pain within the past month, the prevalence of chronic pain will increase dramatically in the coming years. Opioid use for pain is highest among older adults, yet many complain of inadequate relief, significant side effects and increased risk of opioid-related consequences. Medical marijuana (MMJ) use is increasingly common among older adults for pain relief; however, the potential benefits, risks, and negative consequences of MMJ in this population have not been assessed, raising serious public health concerns addressed in this proposal.
PROJECT NARRATIVE Policymakers are increasingly considering state medical cannabis laws as a potential solution to the U.S. opioid crisis, but rigorous evidence is lacking. In this project, we study the effects of state medical cannabis laws on receipt of prescription opioid and guideline-concordant non-opioid treatment, as well as treatment for opioid use disorder, opioid overdose, cannabis use disorder, and cannabis poisoning, among patients with chronic non-cancer pain.
Valid, accurate diagnoses are critical for many purposes: indicating referrals to appropriate treatment; determining eligibility for clinical trials; making accurate prevalence estimates, training clinicians; and for improving DSM-5-TR and potentially DSM-6. Despite the rapidly changing cannabis landscape and increasing use of cannabis for pain, the DSM-5-TR CUD criteria have not been updated since 2013, and the changed legal status of cannabis has left gaps in knowledge about how it is used medically and how existing DSM-5 guidelines for diagnosing substance use disorders for prescribed substances should be adapted for cannabis, which cannot be prescribed but only ‘authorized’. This project will fill major gaps in knowledge about medical use; adapt DSM- 5 CUD criteria and diagnosis using this knowledge; and test the adapted criteria and diagnoses to determine if they improve reliability and validity over the existing DSM-5-TR CUD.
PROJECT NARRATIVE Policymakers are increasingly considering state medical cannabis laws as a potential solution to the U.S. opioid crisis, but rigorous evidence is lacking. In this project, we study the effects of state medical cannabis laws on receipt of prescription opioid and guideline-concordant non-opioid treatment, as well as treatment for opioid use disorder, opioid overdose, cannabis use disorder, and cannabis poisoning, among patients with chronic non-cancer pain.
PROJECT NARRATIVE Policymakers are increasingly considering state medical cannabis laws as a potential solution to the U.S. opioid crisis, but rigorous evidence is lacking. In this project, we study the effects of state medical cannabis laws on receipt of prescription opioid and guideline-concordant non-opioid treatment, as well as treatment for opioid use disorder, opioid overdose, cannabis use disorder, and cannabis poisoning, among patients with chronic non-cancer pain.
PROJECT NARRATIVE The aims of this proposal are to determine the safety and efficacy of Cannabidiol (CBD) to alleviate pain and opioid craving among people living with both opioid addiction and chronic pain. Results will provide evidence as to whether CBD might aid as a novel treatment for this especially vulnerable population. This proposal will accelerate the development of novel therapeutics targeting the endogenous cannabinoid system for opioid addiction and chronic pain, a strategy that is likely to reduce persistently high rates of relapse and save lives.
PROJECT NARRATIVE The aims of this proposal are to determine the safety and efficacy of Cannabidiol (CBD) to alleviate pain and opioid craving among people living with both opioid addiction and chronic pain. Results will provide evidence as to whether CBD might aid as a novel treatment for this especially vulnerable population. This proposal will accelerate the development of novel therapeutics targeting the endogenous cannabinoid system for opioid addiction and chronic pain, a strategy that is likely to reduce persistently high rates of relapse and save lives.
Narrative Drug overdose is the country's leading cause of injury-related death, driven overwhelmingly by a rise in opioid overdoses. Unprecedented changes in cannabis and opioid policies over the last 20 years have placed restrictions on opioid prescriptions and increased legal access to cannabis. This study will inform policymakers about the types and combinations of prescription opioid and cannabis policies that are likely to lead to the greatest reductions in opioid-related harm, with and without benzodiazepines.
Over the next 35 years, the “50+” population will more than double, and as greater than 50% of adults over 65 report bothersome pain within the past month, the prevalence of chronic pain will increase dramatically in the coming years. Opioid use for pain is highest among older adults, yet many complain of inadequate relief, significant side effects and increased risk of opioid-related consequences. Medical marijuana (MMJ) use is increasingly common among older adults for pain relief; however, the potential benefits, risks, and negative consequences of MMJ in this population have not been assessed, raising serious public health concerns addressed in this proposal.
Project Narrative: Over a third of patients with sickle cell disease use some form of cannabinoids to treat their uncontrolled pain, but there is little data to support this and little data on the adverse effects of cannabinoids in patients with sickle cell disease. However, cannabinoids have been shown to treat pain and to reduce markers of inflammation (which contributes to pain itself and to end organ damage) in other diseases of chronic pain and in mouse models of sickle cell disease. This project will study the possible efficacy study of an FDA approved cannabinoid containing product to treat pain and/or reduce inflammation in people living with sickle cell disease while also contributing to the understanding of the possible risks of this use.
Narrative Drug overdose is the country's leading cause of injury-related death, driven overwhelmingly by a rise in opioid overdoses. Unprecedented changes in cannabis and opioid policies over the last 20 years have placed restrictions on opioid prescriptions and increased legal access to cannabis. This study will inform policymakers about the types and combinations of prescription opioid and cannabis policies that are likely to lead to the greatest reductions in opioid-related harm, with and without benzodiazepines.
Showing 12 of 37 frozen records. Browse the complete set →
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
No matching records in this frozen snapshot.
FAERS package linkage is unavailable; zero reports must not be inferred until exact governed medicine links are ready.
Regulatory records
Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D059350 using Medical Subject Headings 2026.
18,209 source identifiers verified · snapshot record 58ed6383b97a...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 6,825 frozen records. Browse the complete set →